Imagion’s breakthrough cancer device in manufacturing milestone

Australian listed medical imaging company Imagion Biosystems has moved a step closer to trialing its breakthrough cancer detection device, with the first phase of manufacture of a nanoparticle formulation completed despite the Covid-19 pandemic. Manufacture of the company’s MagSense HER2 nanoparticle formulation proceeded uninterrupted by the pandemic under good manufacturing practice (GMP) conditions. The second…